Travere Therapeutics Inc
NASDAQ:TVTX

Watchlist Manager
Travere Therapeutics Inc Logo
Travere Therapeutics Inc
NASDAQ:TVTX
Watchlist
Price: 35 USD -0.93% Market Closed
Market Cap: 3.1B USD

Wall Street
Price Targets

TVTX Price Targets Summary
Travere Therapeutics Inc

Wall Street analysts forecast TVTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TVTX is 42.33 USD with a low forecast of 31.31 USD and a high forecast of 51.45 USD.

Lowest
Price Target
31.31 USD
11% Downside
Average
Price Target
42.33 USD
21% Upside
Highest
Price Target
51.45 USD
47% Upside
Travere Therapeutics Inc Competitors:
Price Targets
NBIX
Neurocrine Biosciences Inc
14% Upside
ALT
Altimmune Inc
261% Upside
PBYI
Puma Biotechnology Inc
10% Downside
096530
Seegene Inc
67% Upside
ZYME
Zymeworks Inc
32% Upside
TGTX
TG Therapeutics Inc
47% Upside
002675
Yantai Dongcheng Biochemicals Co Ltd
19% Upside
600161
Beijing Tiantan Biological Products Corp Ltd
44% Upside

Revenue
Forecast

Revenue Estimate
Travere Therapeutics Inc

The compound annual growth rate of Travere Therapeutics Inc's revenue for the next 3 years is 58%.

N/A
Past Growth
58%
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Travere Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Miss

Net Income
Forecast

Net Income Estimate
Travere Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-48%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is TVTX's stock price target?
Price Target
42.33 USD

According to Wall Street analysts, the average 1-year price target for TVTX is 42.33 USD with a low forecast of 31.31 USD and a high forecast of 51.45 USD.

What is Travere Therapeutics Inc's Revenue forecast?
Projected CAGR
58%

The compound annual growth rate of Travere Therapeutics Inc's revenue for the next 3 years is 58%.

Back to Top